A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell Tumors
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Cabozantinib (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer; Seminoma
- Focus Therapeutic Use
- Acronyms CTO-IUSCCC-0752
- 08 Oct 2023 Status changed from suspended to recruiting.
- 19 Jun 2023 Status changed from recruiting to suspended (Due to pending ICF updates ).
- 18 May 2022 Planned number of patients changed from 25 to 50.